Table 1. Clinicopathological characteristics of the study population.
| Stage I–III (n=239) | Stage I–IV (n=287) | |
|---|---|---|
| Age | 64 (27–96) | 64 (27–96) |
|
Sex | ||
| Male | 157 (65.7) | 186 (64.5) |
| Female | 82 (34.3) | 101 (35.2) |
|
Site of disease | ||
| Colon | 102 (42.7) | 134 (46.7) |
| Rectum | 137 (57.3) | 153 (53.3) |
|
T stage | ||
| T0 | 6 (2.5) | 6 (2.1) |
| T1 | 18 (7.5) | 20 (7.0) |
| T2 | 63 (26.4) | 65 (22.6) |
| T3 | 131 (54.8) | 161 (56.1) |
| T4 | 21 (8.8) | 35 (12.2) |
|
N Stage | ||
| N0 | 155 (64.9) | 170 (59.2) |
| N1 | 59 (24.7) | 76 (26.5) |
| N2 | 25 (10.5) | 41 (14.3) |
|
Resection margins | ||
| R0 | 223 (97.4) | 262 (96.3) |
| R1 | 6 (2.6) | 10 (3.7) |
| Tumour height (cm) | 7.3 (0–18) | 7.4 (0–18) |
|
Distribution of metastases | ||
| Liver | — | 32 (66.7) |
| Lung | — | 6 (12.5) |
| Other | — | 7 (14.6) |
| Multiple sites | — | 3 (6.2) |
| Neoadjuvant therapy | 81 (33.9) | 95 (33.1) |
| Neoadjuvant radiation | 81 (33.9) | 87 (30.0) |
| Adjuvant therapy | 57 (36.5) | 83 (43.7) |
| Follow-up (months) | 28 (0–53) | 28 (0–53) |
| CEA (>2.5 U l−1) | 54 (24) | 87 (32.0) |
| CA 19-9 (>37 U l−1) | 24 (10.7) | 39 (14.3) |
Abbreviation: CEA=carcinoembryonic antigen.